Stockreport

Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual...

Innate Pharma S.A. - American Depositary Shares  (IPHA) 
PDF Efficacy results, analyzed according to updated lymph node involvement classification, confirm clinical activity and favorable safety profile of lacutamab in advanced My [Read more]